Gilead Sciences, Inc. $GILD Holdings Reduced by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 91.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,141 shares of the biopharmaceutical company’s stock after selling 74,087 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Gilead Sciences were worth $793,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after acquiring an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares during the period. Norges Bank acquired a new position in shares of Gilead Sciences during the second quarter valued at $2,150,268,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after purchasing an additional 1,520,809 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on GILD shares. BMO Capital Markets set a $135.00 target price on shares of Gilead Sciences in a research note on Tuesday, November 25th. TD Cowen raised their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. UBS Group raised Gilead Sciences to a “hold” rating in a research note on Thursday, December 4th. Finally, Mizuho boosted their price objective on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.54.

Gilead Sciences Price Performance

NASDAQ GILD opened at $124.16 on Tuesday. The stock has a market capitalization of $154.04 billion, a P/E ratio of 19.25, a P/E/G ratio of 0.69 and a beta of 0.32. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The business’s fifty day moving average is $122.47 and its two-hundred day moving average is $116.31. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00. Following the sale, the chief executive officer owned 571,203 shares in the company, valued at $72,280,027.62. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 136,257 shares of company stock worth $16,723,492. 0.27% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.